Phase I study of peptide vaccination in patients with refractory gastrointestinal cancer

Phase I study of peptide vaccination in patients with refractory gastrointestinal cancer - GI Peptide Vaccination

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008820

Enrollment

Registered

2012-09-03

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal cancer

Interventions

Vaccination of 10 peptides

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) refractory gastrointestinal cancer 2) with or without measurable lesion 3) enable to ingestion 4) ECOG PS 0 or 1 5) age 20-80 years 6) preserved organ functions 7) written informed consent 8) more than 3 months of expected survival period

Exclusion criteria

Exclusion criteria: 1) active double cancer 2) active infection 3) pregnancy, the desire to preserve fecundity, or lactating woman 4) mental disorder 5) steroid treatment 6) uncontrolled diabetes mellitus 7) unstable angina or myocardial infarction within 6 months 8) other severe complications 9) active bleeding 10) massive ascites 11) massive pleural effusion 12) HBs antigen-positive

Design outcomes

Primary

Measure	Time frame
To evaluate dose-limiting toxicity and immune response	—

Countries

Japan

Contacts

Public ContactSatoru Iwasa

National Cancer Center Hospital Gastrointestinal Oncology Division

siwasa@ncc.go.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026